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Summary
Chronic disorders, such as obesity, diabetes, inflammation,
non-alcoholic fatty liver disease and atherosclerosis, are
related to alterations in lipid and glucose metabolism, in
which peroxisome proliferator-activated receptors
(PPAR)α, PPARβ/δ and PPARγ are involved. These re-
ceptors form a subgroup of ligand-activated transcription
factors that belong to the nuclear hormone receptor family.
This review discusses a selection of novel PPAR functions
identified during the last few years. The PPARs regulate
processes that are essential for the maintenance of preg-
nancy and embryonic development. Newly found hepatic
functions of PPARα are the mediation of female-specific
gene repression and the protection of the liver from oestro-
gen induced toxicity. PPARα also controls lipid catabolism
and is the target of hypolipidaemic drugs, whereas PPARγ
controls adipocyte differentiation and regulates lipid stor-
age; it is the target for the insulin sensitising thiazolidine-
diones used to treat type 2 diabetes. Activation of PPARβ/δ
increases lipid catabolism in skeletal muscle, the heart and
adipose tissue. In addition, PPARβ/δ ligands prevent
weight gain and suppress macrophage derived inflamma-
tion. In fact, therapeutic benefits of PPAR ligands have
been confirmed in inflammatory and autoimmune diseases,
such as encephalomyelitis and inflammatory bowel dis-
ease. Furthermore, PPARs promote skin wound repair.
PPARα favours skin healing during the inflammatory phase
that follows injury, whilst PPARβ/δ enhances keratinocyte
survival and migration. Due to their collective functions in
skin, PPARs represent a major research target for our un-
derstanding of many skin diseases. Taken altogether, these
functions suggest that PPARs serve as physiological
sensors in different stress situations and remain valuable
targets for innovative therapies.
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syndrome; inflammation; skin wound healing
Introduction
Metabolic syndrome is defined as the combination of mul-
tiple metabolic disorders, including obesity, dyslipidaemia,
glucose intolerance, inflammation and hypertension. The
pathophysiology determining this syndrome involves an in-
teraction of key factors, but two of these, insulin resistance
and obesity, play major roles. Moreover, low grade inflam-
mation has appeared to be a link between insulin resistance,
obesity and type 2 diabetes [1]. In recent years, a number of
studies showed that a family of transcription factors, named
the peroxisome proliferator-activated receptors (PPARs),
improved several of the metabolic abnormalities associated
with the metabolic syndrome.
The PPARs are ligand-activated transcription factors
which belong to the nuclear hormone receptor superfamily
[2–4]. Three isotypes have been identified in lower ver-
tebrates and mammals: PPARα or NR1C1, PPARβ/δ or
NR1C2, also called NUC-1 or FAAR, and PPARγ or
NR1C3 [5]. These receptors exhibit different tissue distri-
bution and functions and, to some extent, different ligand
specificities [6]. Mechanistically, they form heterodimers
with the retinoid X receptor (RXR) and activate transcrip-
tion by binding to a specific DNA element, termed the
peroxisome proliferator response element (PPRE), in the
regulatory region of a variety of genes encoding proteins
that are involved in lipid metabolism and energy balance
[7–9]. Binding of agonists within the ligand-binding site of
PPARs causes a conformational change promoting binding
to transcriptional coactivators. Conversely, binding of ant-
agonists results in a conformation that favours the binding
of corepressors [10, 11]. Physiologically, PPAR-RXR het-
erodimers may bind to PPREs in the absence of a ligand.
Although the transcriptional activation depends on the
ligand-bound PPAR-RXR, the presence of unliganded
PPAR-RXR at a PPRE has effects that vary depending on
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the promoter context and cell type. For example, for some
PPARγ target genes in adipocytes, unliganded PPARγ-
RXR heterodimers recruit corepressor complexes, resulting
in active repression, whereas for other genes, corepressors
are not recruited by unliganded PPARγ-RXR [12]. There
are a variety of potential endogenous ligands for the
PPARs, such as fatty acids, in particular unsaturated fatty
acids, several eicosanoids and metabolites of linoleic acid,
which bind to the PPARs with varying affinities, resulting
in transcriptional activation of target genes. Synthetic,
high-affinity selective ligands for each of the PPARs are
also available, as well as dual-specificity ligands that bind
with high affinity to these receptors [12].
The predominant role of these receptors, as presently
understood, is the transcriptional regulation of enzymes
and other proteins involved in energy homeostasis. In addi-
tion, crucial roles of PPARα in sexual dimorphism and of
PPARβ/δ in tissue repair have also been unveiled [13, 14].
The aim of this review is to summarise new knowledge
on the roles of PPARs in the regulation of various physiolo-
gical and pathophysiological situations, such as energy
metabolism in health and diseases, inflammation, sexual
dimorphism and tissue repair.
The role of PPARα in sexualdimorphism
During the past decade, a large number of studies concen-
trated on the main roles of PPARs in energy metabolism
and inflammation in response to dietary and endogenous
signals. However, their roles extend far beyond these areas.
It is common knowledge that the liver, in humans as well
as in rodents, plays a crucial role in several gender-depend-
ent metabolic pathways. In fact, the mammalian liver is
the centre for sex-specific controls that contribute, in par-
ticular, to differences in steroid hormone metabolism and
the degradation of xenobiotics. In addition, in both humans
and mice, gender affects hepatic inflammatory responses
and hepatocellular carcinoma development [15–18]. Many
of the 1600 hepatic genes differentially expressed between
sexes in the mouse liver are regulated by differences in
pituitary growth hormone secretion, which is pulsatile in
males and continuous in females. In fact, among the main
liver proteins, the cytochrome P450 (CYP) enzymes meta-
bolise diverse steroids, fatty acids and many lipophilic
drugs [19, 20]. Though most pronounced in rat and mouse
livers, sex differences in CYP expression also occur in
humans [21]. The oxysterol 7α-hydroxylase cytochrome
P450-b1 (CYP7b1) protein, a prominent member of the
CYP family, is highly expressed in male compared to fe-
male livers [22–25]. This enzyme has antagonistic actions
on sexual hormone production. It negatively regulates the
bioavailability of testosterone, the male sexual hormone,
and promotes oestrogen receptor (ER) activity by catalys-
ing the clearance of 27-hydroxycholesterol, which func-
tions as a competitive ER antagonist [23, 26]. The activated
ER indirectly enhances the expression of CYP7b1, which
participates in oestrogen-induced inflammation and hep-
atotoxicity [27]. Oestrogen-induced hepatotoxicity affects
susceptible women using oestrogen-containing oral contra-
ceptives or postmenopausal hormone replacement therapy
[27]. Moreover, oestrogens cause intrahepatic cholestas-
is, the most common hepatic disease during pregnancy,
which can result in intrauterine foetal death or spontaneous
premature delivery [28]. The cross-talk between ER and
PPARα signalling prompted investigation of the role of
PPARα in the sex-dependent hepatic gene expression re-
lated to steroid metabolism and immunity. Interestingly,
sumoylated PPARα mediates female-specific gene repres-
sion and protects the liver from oestrogen-induced toxicity
in mice [13] (fig. 1A-B). This sex-specific PPARα-depend-
ent gene repression was elucidated using the steroid
CYP7b1 gene as a model. The initial sumoylation of the
ligand-binding domain of PPARα triggers the interaction
of PPARα with the transcription factor GA-binding protein
α (GABPα) bound to the Cyp7b1 promoter. This interac-
tion results in the recruitment of histone deacetylase as
well as DNA and histone methyltransferases to the pro-
moter. It results in promoter-specific histone deacetylation
and methylation, and DNA methylation of a Sp1-binding
site adjacent to the GABP binding sites. These events cause
the loss of Sp1-stimulated expression of CYP7b1 and thus
its downregulation (fig. 1B). Physiologically, this PPARα-
dependent gene repression confers protection against
oestrogen-induced intrahepatic cholestasis in female mice.
In women, oestrogen-induced intrahepatic cholestasis is
the most common hepatic disease during pregnancy. The
abovementioned findings suggest PPARα as a possible
therapeutic target for the prevention or treatment of this
disease.
The roles of PPARs in health and disease
The cellular and systemic roles that have been attributed
to PPARs extend far beyond the control of hepatic perox-
isome proliferation in rodents after which these receptors
were initially named [29] (fig. 2). For instance, they have
coordinating roles in foetal and early postnatal develop-
ment [30]. PPARα is highly expressed in the liver, brown
adipose tissue, heart, skeletal muscle, kidney and in other
organs at lower levels. PPARγ is highly expressed in
adipose tissues and is also present in colon and lymphoid
organs. PPARβ/δ is expressed ubiquitously, but its levels
may vary to a large extent [2].
PPARα
In the liver, PPARα promotes fatty acid oxidation. It is the
target for the fibrate class of hypolidaemic drugs such as
fenofibrate, clofibrate, and gemfibrozil, which are used for
treating hypertriglyceridaemia [7–9]. The role of PPARα in
hepatic fatty acid metabolism is especially prominent dur-
ing fasting (fig. 3A). In fasted PPARα-null mice, its ab-
sence is associated with pronounced hepatic steatosis, de-
creased levels of plasma glucose and ketone bodies, elev-
ated plasma free fatty acid levels and hypothermia [31–33].
These severe metabolic disturbances are the result of the
decreased expression of a large number of genes involved
in hepatic lipid metabolism, many of which have been
identified as direct PPARα target genes [34, 35]. In addi-
tion, PPARα is a target of hypothalamic hormone signalling
as it plays an important role in the anti-inflammatory action
of glucocorticoids [36]. In fact, during fasting, as well as
in situations of physical and physiological stress, the hypo-
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thalamic ACTH induces the release of glucocorticoids by
the adrenal glands, which stimulates the hepatic expression
of PPARα (fig. 3A). Moreover, it accumulates according to
a daily rhythm with highest levels at the beginning of feed-
ing time [37] (fig. 3A). The availability and production of
physiologically relevant ligands of PPARα is central for co-
ordinating its multiple functions in response to the amount
and type of food available (fig. 3B) [38, 39].
Interestingly, PPARα is involved in embryonic devel-
opment and the viability of pups [30]. Although PPARα-
null mice are viable, they present an increased risk of ma-
ternal abortion and neonatal mortality [40]. In fact, roughly
50% of diabetic PPARα-deficient mice abort between day
12 and 16 of gestation and approximately 80% of their off-
spring die at birth [40]. Several reasons have been sugges-
ted for this increased mortality. Gemfibrozil and clofibrate,
two PPARα agonists, down-regulate human chorionic gon-
adotrophin and up-regulate progesterone secretions in hu-
man trophoblast cells, suggesting that a lack of PPARα may
be deleterious for the secretion of these hormones, essential
for maintaining pregnancy [41]. PPARα is expressed in the
placenta in late gestation and all three PPARs (α, β/δ and
γ) are expressed in junctional (endocrine functional) and
labyrinth (barrier transport) zones of the rat placenta, from
day 13–21 of gestation [42, 43]. PPARα has also been ob-
served in the human term placenta, suggesting a potential
role in placental fatty acid transfer to meet foetal require-
ments [43]. These observations show that even if PPARα-
null mothers are able to accumulate lipids in the placenta
labyrinth, due to the presence of PPARγ, the lack of PPARα
may affect foetal-maternal nutrient exchange, which may
explain, at least in part, the lethality mentioned above. This
placental dysfunction may be more pronounced in diabetes,
which increases energy demands. In fact, PPARα-null dia-
betic mice are hypoinsulinaemic, with a reduced ability to
use glucose and lipids as energy sources [40]. Therefore, in
addition to hormonal dysfunctions and the high proinflam-
matory Th1 cytokine levels observed in pregnant PPARα-
null diabetic mice and their offspring, the high rate of abor-
tion and mortality rate of pups could also be related to the
defect in energy utilisation.
PPARγ
While PPARα controls lipid catabolism and homeostasis in
the liver, PPARγ promotes the storage of lipids in adipose
tissues. PPARγ is abundantly expressed in adipocytes and
plays a pivotal role in adipocyte differentiation [44]. It is a
target of the insulin-sensitising thiazolidinediones, a class
of drugs which are widely used for the treatment of type
2 diabetes [45] (fig. 2). Despite its relatively low expres-
sion levels in healthy liver, PPARγ is critical for the de-
velopment of hepatic steatosis [46, 47]. The functions of
PPARγ extend far beyond fat storage and adipocyte dif-
ferentiation. For instance, it has a recently recognised role
in promoting osteoclast differentiation and bone resorp-
tion when activated by rosiglitazone [48]. Its deletion in
mouse osteoclast precursors leads to increased bone mass
and density and extramedullary haematopoiesis. This phen-
otype corresponds to the clinical syndrome called osteo-
petrosis, associated with impaired osteoclast differentiation
from haematopoietic stem cells. Conversely, PPARγ down-
regulates osteogenesis. In fact, it influences the competi-
tion between adipogenic and osteoblastic differentiation of
bone marrow progenitors in favour of adipogenesis [49,
50]. Furthermore, all PPARγ-null embryos die at an early
developmental stage because of placental defects including
impaired vascularisation [51, 52].
PPARβ/δ
This isotype is ubiquitously expressed and is implicated
in diverse processes ranging from the regulation of energy
homeostasis, thermogenesis, to keratinocyte proliferation
and differentiation during wound healing [9]. It stimulates
the β-oxidation of fatty acids and reverses cholesterol
transport, which lead to the proposal of PPARβ/δ ligands
as potential drugs for treating metabolic syndrome [53].
While various physiological functions of PPARβ/δ are still
being investigated, roles are already documented in embryo
implantation [54], myelination in the brain [55] and os-
teoclastic bone resorption [56]. Furthermore, its multiple
implications in lipid metabolism comprise preadipocyte
clonal expansion [57], fatty acid oxidation in muscle [58]
and lipoprotein homeostasis [59]. As with PPARα and γ,
polyunsaturated fatty acids have a relatively high affinity
for PPARβ/δ and a number of eicosanoids, particularly
prostacyclin, which is a cyclooxygenase-2 arachidonate
metabolite, were shown to activate PPARβ/δ [60].
A key tool for understanding PPAR functions in
physiology has been the generation PPAR-null mice. Many
PPARβ/δ-null embryos die at an early developmental stage.
In fact, PPARβ/δ deletion affects placenta morphogenesis
resulting in partial embryonic lethality at embryonic day
(E) 9.5 to E10.5 [51]. The trophoblast giant cell layer is
most affected, reflecting the involvement of PPARβ/δ in
trophoblast cell differentiation toward giant cells [51].
These cells are the primary sites of lipid accumulation
in the placenta at an early stage, which correlates with
PPARβ/δ-dependent up-regulation of adipose
differentiation-related protein (ADRP) expression [51]. In
brief, these genetic approaches helped unveil important as-
pects of the development and functions of the giant cell lay-
er and their impact on placental development.
Limited information is available on PPARβ/δ in the liv-
er, even though it is well expressed in this organ, partic-
ularly in endothelial cells and hepatocytes [61, 62]. Data
suggest that PPARβ/δ is protective against liver toxicity in-
duced by environmental chemicals, possibly by down-reg-
ulating the expression of pro-inflammatory genes [63]. To
better understand the function of PPARβ/δ in the liver, the
effects of PPARα and PPARβ/δ deletion were compared us-
ing whole genome transcriptional profiling. The data ob-
tained provide evidence that PPARβ/δ governs glucose util-
ization and lipoprotein metabolism and has an important
anti-inflammatory role in the liver. In fact, they underscore
divergent roles of PPARα and PPARβ/δ in the regulation
of gene expression in this organ [64]. Furthermore, in the
β-cell line INS-1E, PPARβ/δ protects glucose-stimulated
insulin secretion (GSIS) against adverse effects associated
with prolonged fatty acid exposure [65]. Finally, a selective
activation of PPARβ/δ was shown to promote reverse cho-
lesterol transport [59].
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Activation of PPARβ/δ increases lipid catabolism in
skeletal muscle, the heart and adipose tissue and improves
the serum lipid profile and insulin sensitivity in animal
models. It has a crucial role in the distribution of skeletal
muscle fibre types [58]. After selective deletion of
PPARβ/δ in skeletal muscle, mice exhibit a switch in
muscle fibre types toward a lower oxidative capacity that
precedes the development of obesity and diabetes, thus
demonstrating that PPARβ/δ is instrumental in myocytes
for the maintenance of oxidative fibres and that fibre-type
switching is likely to be the cause and not the consequence
of these metabolic disorders [58]. In addition, PPARβ/δ
ligands prevent weight gain and suppress macrophage-de-
rived inflammation [66].
In light of all these reports, PPARs appear to be targets
for the treatment of metabolic disorders amongst others. In
fact, PPARα and PPARγ are already therapeutic targets for
the treatment of hypertriglyceridaemia and insulin resist-
ance, respectively. Evidence is now emerging that PPARβ/δ
may also be a potential pharmacological target for the treat-
ment of various metabolic disorders. However, the debate
concerning the pro- and anti-cancer properties of this re-
ceptor is still open and calls for a scrupulous and thorough
assessment of the safety of putative PPARβ/δ drugs.
PPARs and inflammation
In addition to many other cell types, PPARs are expressed
in dendritic cells, macrophages, and B and T lymphocytes,
suggesting a role in immunity. They are also expressed in
epithelial cells, which have an essential function in the mu-
cosal immune response. In line with these observations,
many studies have confirmed a therapeutic activity of
PPAR ligands in several rodent models of inflammatory
and autoimmune diseases [67–69]. For instance, PPARβ/δ
ligands have beneficial effects in experimental autoim-
mune encephalomyelitis (EAE) [70]. PPARα is also found
in endothelial cells where it regulates the expression of
leukocyte adhesion molecules. In mutant mice, PPARα de-
ficiency shifts the Th1/Th2 balance towards the pro-in-
flammatory Th1 phenotype [40]. This inflammatory status
of PPARα-null mice is exacerbated in the context of dia-
betic pregnancy and increases the risk of maternal abortion
and neonatal mortality (see above). In fact, upon ligand
activation, PPARα down-regulates diverse components of
Figure 1
Sumoylation-dependent transrepression by PPARα is sex-dependent.
A.) Model of the ligand-binding domain (LBD) of mouse PPARα in the ligand-activated
conformation (upper left panel). Lysine 358 (K358) in Helix 7 of the LBD of PPARα is
sumoylated in female hepatocytes and is presented at the surface of the LBD upon
agonist binding. This lysine is conserved in the corresponding position of Helix 7 of
PPARγ and PPARβ/δ (upper right panel). The change of conformation of Helix 12, which
is induced by a PPARα agonist, increases the accessibility of K358 for sumoylation (lower
left panel). In contrast, K358 is masked in the presence of an antagonist (lower right
panel). The NH-end helix (Helix 1) and COOH-helix (Helix 12) of the ligand binding
domain are in pink, Helix 7 with its sumoyalated lysine (K358) in red and the β-sheets in
orange.
B.) Model of PPARα-induced repression of Cyp7b1 in females. Sumoylation of PPARα
promotes interaction with GABPs and leads to the recruitment of NCoR, HDACs, histone
and DNA methyltransferases. These events lead to histone H3 deacetylation, tri-
methylation and DNA methylation at the Sp1 binding site, which results in Sp1
displacement and down-regulation of gene expression. After genetic removal of PPARα in
female mice the repression complex does not form, which leads to stimulation of Cyp7b1
expression [13].
Cyp7b1, oxysterol 7α-hydroxylase cytochrome P450-b1; HDAC, histone deacetylase; Dnmt, DNA methyltransferase; GABP, GA-binding
protein.
Figure 2
Metabolic functions of PPARs.
Compilation of the known main metabolic functions of PPARα, PPARβ/δ and PPARγ in
the liver, muscle, adipose tissue and pancreas.
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the pro-inflammatory response such as chemokines and
cytokines by decreasing the expression of the Th1 tran-
scription factor T-bet (T-box expressed in T cells) and in-
creasing the expression of GATA-3 (guanosine adenosine
thymidine adenosine 3), known as a positive regulator of
Th2 cytokines [71]. PPARα agonists inhibit the transcrip-
tional activity of NF-κB (nuclear factor-κB), AP-1 (activat-
or protein 1), GATA and NFAT (nuclear factor of activated
T-cells), which mediate the induction of genes responsible
for the development of inflammation and cardiac hyper-
trophy [72, 73] (fig. 4). The increased severity of inflam-
matory diseases in PPAR-deficient mice suggests an anti-
inflammatory role for either unliganded PPAR or PPAR
activated by endogenous ligands [74, 75]. In chronic in-
flammation, ligand-bound PPARα represses the production
of pro-inflammatory IFN-γ and IL-17 by CD4+ T cells and
PPARγ ligands modulate the function of dendritic cells to
elicit the development of anergic CD4+ T cells [76]. In
macrophages, PPARγ ligands repress the expression of a
subset of Toll-like receptor (TLR) target genes by a mo-
lecular mechanism termed ligand-dependent transrepres-
sion [74]. The PPAR ligands also repress the expression of
cell adhesion molecules on endothelial cells and the secre-
tion of chemokines by epithelial and other cells, decreas-
ing the recruitment of leukocytes to the site of inflamma-
tion [76]. The anti-inflammatory activity of PPAR ligands
in mouse models encourages the evaluation of the possibil-
ity of PPARs as targets for the treatment of human inflam-
matory and autoimmune diseases. In fact, PPARα agonists
have already been suggested against cardiovascular inflam-
matory responses. Along the same line of thought, the
PPARα agonist fenofibrate is a potent anti-inflammatory
drug used in the treatment of patients with rheumatoid arth-
ritis [77]. When used as a lipid-lowering agent in patients
with atherosclerosis, fenofibrate induces a decrease in cir-
culating TNF-α, IL-1β and IFN-γ [78]. Finally, the PPARγ
agonists thiazolidinediones efficiently normalise skin ho-
meostasis when orally administrated to patients suffering
from psoriasis, suggesting that their beneficial effects are
most likely due to systemic antiinflammatory functions
of PPARγ (reviewed in [79]). These reports underscore a
promising therapeutic benefit of PPAR ligands in the treat-
ment of inflammatory diseases.
Figure 3
PPARα regulation and activation in the liver.
A.) PPARα expression is stimulated by glucocorticoids (HPA axis; left panel) and follows a
circadian rhythm with the highest expression at the end of the light phase (right panel).
Lipolysis of triglycerides stored in adipose tissues provides free fatty acids (FFA) and
glycerol to the liver, via blood circulation, where they are used for ketone body and
glucose production, respectively.
B.) Simplified scheme illustrating the production of ligands activating PPARα. Dietary fatty
acids and fatty acid derivatives activate PPARα. On a high sucrose (no fat diet), the
production of 16:0/18:1 GPC activates PPARα [38, 39]. Activation of PPARα results in the
transcriptional regulation of numerous genes, the so-called PPARα transcriptome, which
contributes to maintaining the energy balance in part through the promotion of
mitochondrial and peroxisomal beta-oxidation of fatty acids and many other metabolic
pathways.
FA, fatty acids; 16:0/18:1 GPC, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine; TG,
triglycerides; VLDL, very low density lipoprotein.
Figure 4
Anti-inflammatory effects of PPAR ligands.
Cellular targets of the anti-inflammatory actions of PPARs activated by both endogenous
and synthetic ligands. Ligand-activated PPARs down-regulate or up-regulate diverse
components of the inflammatory response. The PPARβ/δ ligands activate the co-
repressor BCL-6, inhibit the activity of NF-κB and ERK1/2 and induce anti-inflammatory
and antioxidant genes. At the site of inflammation, PPARβ/δ ligands reduce the levels of
adhesion molecules (ICAM-1, VCAM-1, E-selectin), pro-inflammatory cytokines (TNFα,
IL-6, IL1β, IFNγ), chemokines (MCP-1, -3, -5, MIP1α) and chemokine receptors (CCR2).
Furthermore, PPARβ/δ and its endogenous ligands are induced during the inflammatory
phase of wound healing and promote keratinocyte migration and survival (Integrin-like
kinase and Akt pathways). Antioxidant targets (SOD: superoxide dismutase, CAT:
catalase, and thioredoxin) are also induced by PPARβ/δ ligands. The PPARα agonists inhibit transcription factors NF-κB, AP-1, GATA, and
NFAT, which mediate the induction of genes responsible for the development of inflammation and cardiac hypertrophy. Moreover, PPARα
ligands (fibrates, WY14,643) inhibit the production of Th1 cytokines (IFN-γ, IL-2, IL-17) and induce that of Th2 cytokines (IL-10, IL-4, IL-5) by T
cells. Th, T helper cell; (+) positive regulation; (-) negative regulation.
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PPARs are involved in tissue and skinwound repair
The three PPAR isotypes are expressed in rodent and hu-
man skin. In addition to their roles in lipid and glucose
homeostasis and inflammation (see above), their import-
ance in skin wound healing has emerged more recently [80,
81]. After a skin injury, the healing process requires the
covering of the wound bed with a new protective epiderm-
is. This process comprises several phases: inflammation,
re-epithelialisation and remodelling of the scar. The initial
inflammatory response is followed by the proliferation and
migration of keratinocytes, with a parallel dermal repair
comprising the activation and proliferation of fibroblasts
and angiogenesis. Importantly, PPARα and β/δ are instru-
mental in this repair process, with each of them playing
specific roles [80]. The PPARα isotype is mainly involved
in the initial inflammation phase of the pro-cess. It was
shown that PPARα-null mice exhibit impaired recruitment
of neutrophils and monocytes/macrophages to the wound
bed and present a transient delay in healing, which coin-
cides with the inflammatory phase [80]. Transgenic mice
with a selective decrease of PPARα activity in keratino-
cytes only display a similar phenotype, which reveals the
importance of keratinocytes in orchestrating the inflam-
matory process [82]. While the expression of PPARα is
transiently up-regulated and is parallel to the inflammatory
phase, that of PPARβ/δ in keratinocytes lasts throughout
the entire healing process. In agreement with these obser-
vations, the completion of skin healing is postponed by two
to three days in PPARβ/δ-null mice [80]. PPARβ/δ is an im-
portant regulator of keratinocyte survival in the wounded
epidermis and is involved in cell adhesion and migration
[81] (fig. 5A). In particular, a novel homeostatic control of
keratinocyte proliferation and differentiation was recently
found, whereby PPARβ/δ regulates the signalling of IL-1
in dermal fibroblasts [83] (fig. 5B). The role of PPARγ ap-
pears to be rather minor in keratinocytes, whereas its activ-
ity is required for sebaceous gland differentiation. Indeed,
activation of PPARγ with troglitazone and prostaglandin-J2
does not affect epidermal maturation in foetal rat skin [84].
However, topical treatments with the PPARγ agonists trogl-
itazone and ciglitazone increase the expression of differen-
tiation markers and promote epidermal barrier recovery in
hairless mice [85].
To sum up, we can conclude that PPARα and PPARβ/δ
both play important roles in skin wound repair with
isotype-specific timing. PPARα favours skin healing via
modulation of the inflammatory phase, whilst PPARβ/δ
plays an important role in keratinocyte survival and migra-
tion. Due to their collective diverse functions in skin bio-
logy, PPARs represent major research targets for the un-
derstanding and treatment of many skin diseases, such as
benign epidermal tumours, papillomas, acne vulgaris and
psoriasis.
Conclusion
There are many major cellular and physiological functions
regulated by PPARs. At the molecular level, these receptors
mainly act through ligand-dependent target gene activation.
However, there is increasing evidence for additional modes
of action such as transrepression and constitutive activation
of the receptors, which also play important roles in PPAR-
mediated signalling. Mechanistic studies highlighted
promoter-specific regulations occurring through coordin-
ated actions of coregulators and through the integration of
extra- and intra-cellular signalling pathways via post-trans-
lational modifications.
One major result of cellular PPAR action is the balance
between cell proliferation, survival and differentiation, as
illustrated by the control of key processes such as wound
healing. The potential tumourigenic action of PPARs in
specific situations deserves important attention, especially
when considering the design of a second generation of
PPAR agonists.
As lipid sensors, PPARs locally tune gene expression
to the metabolic status and thereby coordinate inter-organ
communications in developmental, metabolic and immune
response processes. The use of mouse models with specific
Figure 5
Roles of PPARβ/δ in skin wound healing.
A.) The expression of the pparβ/δ gene is increased via binding of the AP-1 transcription
factor complex to its promoter, which is triggered by activation of the stressassociated
protein kinase pathway by pro-inflammatory cytokines such as TNF-α. In parallel, the
release of pro-inflammatory cytokines also induces the production of PPARβ/δ ligands in
the wounded epithelium. The activated PPARβ/δ protein stimulates the genes coding for
integrin-linked kinase (ILK) and 3-phosphoinositide-dependent kinase-1 (PDK1), which
results in activation of the PKBα/Akt1 anti-apoptotic pathway. Once epithelialisation is
completed, TNF-α-induced pparβ/δ expression is repressed by TGFβ-1 signalling which
inhibits AP-1 binding to the pparβ/δ promoter.
B.) Cell-autonomous and -nonautonomous effects of PPARβ/δ. PPARβ/δ promote
keratinocyte survival differentiation and migration via AKT1 and Rho GTPases in a cell-
autonomous manner. Their proliferation is regulated in a non autonomous fashion via a
paracrine mechanism. IL-1 that is produced by keratinocytes activates c-Jun in dermal fibroblasts via TAK1. c-Jun is an obligate partner of the
AP-1 transcription complex which stimulates the expression of several mitogenic factors. In fibroblasts, PPARβ/δ attenuates IL-1 signalling via
the production of sIL-1ra, whose gene is a direct PPARβ/δ target. The sIL-1ra has little affinity for IL-1R2, which is highly expressed in
keratinocytes. However, it binds with high affinity to IL-1R1 expressed by the fibroblasts. Therefore, sIL-1ra acts as an autocrine antagonist of
IL-1 signalling in fibroblasts. The binding of sIL-1ra to IL-1R1 down-regulates IL-1-mediated signalling events. Consequently, the production of
several AP-1-mediated mitogenic factors is down-regulated, which leads to reduced keratinocyte proliferation due to decreased signalling by
mitogenic factors mediated by their cognate receptors (R) at the surface of keratinocytes. In brief, PPARβ/δ in fibroblasts has an important
homeostatic function in maintaining epidermal homeostasis. The absence of PPARβ/δ results in significant keratinocyte proliferation.
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PPAR gain and loss of function in key organs has con-
tributed to a better understanding of the multifaceted roles
of PPARs and, in the future, will help unveil their input
in the regulatory signalling and gene networks controlling
the key functions of these organs. The PPARs still have
many secrets to be unveiled, ranging from their molecular
actions to their physiological outputs. New technologies
allowing genome-wide studies will undoubtedly uncover
exciting and intricate actions of PPARs, which hopefully
will help in the design of novel targeted pharmacological
strategies.
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